Loading...
Trial of canakinumab, an IL-1β receptor antagonist, in patients with inclusion body myositis
OBJECTIVE: To assess whether canakinumab, a monoclonal antibody against IL-1β approved for autoinflammatory diseases, is effective as target-specific therapy in patients with sporadic inclusion body myositis (sIBM). METHODS: Because in sIBM IL-1β colocalizes with amyloid precursor protein and upregu...
Na minha lista:
| Udgivet i: | Neurol Neuroimmunol Neuroinflamm |
|---|---|
| Main Authors: | , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Lippincott Williams & Wilkins
2019
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6624107/ https://ncbi.nlm.nih.gov/pubmed/31355317 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1212/NXI.0000000000000581 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|